EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population‐based study

Nikolaj Mannering iD, Dennis Lund Hansen iD, Anton Pottegård iD, Henrik Frederiksen iD

Transfusion · 2023

DOI: 10.1111/trf.17212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Nikolaj Mannering und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Hematologic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonden til Lægevidenskabens Fremme, Gangstedfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have investigated long‐term survival in patients with primary immune thrombocytopenia (pITP). Further, changes in prognosis over the past decades and prognosis of secondary immune thrombocytopenia (sITP) are largely unstudied. Our objectives were to study comorbidity‐adjusted prognostic changes and causes of death in chronic pITP and sITP patients. Study Design/Methods Using nationwide Danish health registries 1980–2016, we identified 1762 patients with chronic pITP (median age 58 (IQR, 37–73) years) and 128 with chronic sITP (median age 59 (IQR, 40–73) years). Patients were age‐sex‐matched to 74,781 general population comparators. Comorbidity was assessed using Charlson Comorbidity Index (CCI).

Results

Overall median survival was reduced by 5.1 years (95% CI, 0.7–9.4) ( p < .001) for pITP and 11.1 years (95% CI, 5.8–16.4) ( p < .001) for sITP. 5‐year survival increased from 69% (95% CI, 59–78) in 1980–89 to 80% (95% CI, 75–83) in 2010–16 for pITP, and decreased from 100% (95% CI, 89–98) to 64% (95% CI, 87–91) for sITP. However, numbers were small for sITP. 5‐year survival for pITP with high CCI was 41% (95% CI, 32–49), and 85% (95% CI, 83–87) for low CCI. Bleeding, infection and hematological cancer were relatively frequent causes of death with adjusted subhazard ratios of 3.25 (95% CI, 2.33–4.52), 1.53 (95% CI, 1.08–2.16) and 2.16 (95% CI, 1.12–4.16) in pITP respectively, and 10.52 (95% CI, 1.43–77.36) for hematological cancer in sITP.

Conclusions

Long‐term survival is reduced in chronic ITP but seems to be improving. Comorbidity and sITP are associated with a poor prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicHematologic NeoplasmsHumansAdultMiddle AgedComorbidityPrognosisHemorrhage

Stichwörter der Autor:innen

causes of deathepidemiologyimmune thrombocytopenialong-term survival

Autor:innen und Institutionen

  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Public Health, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Nikolaj Mannering, Dennis Lund Hansen, Anton Pottegård, Henrik Frederiksen

Förderung

  • Fonden til Lægevidenskabens Fremme
  • Gangstedfonden

Zitieren

APA

Mannering, N., Hansen, D. L., Pottegård, A., & Frederiksen, H. (2023). Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population‐based study. Transfusion. https://doi.org/10.1111/trf.17212

Vancouver

Mannering N, Hansen DL, Pottegård A, Frederiksen H. Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population‐based study. Transfusion. 2023. doi:10.1111/trf.17212

BibTeX
@article{Mannering2023,
  author = {Mannering, Nikolaj and Hansen, Dennis Lund and Pottegård, Anton and Frederiksen, Henrik},
  title = {Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population‐based study},
  journal = {Transfusion},
  year = {2023},
  doi = {10.1111/trf.17212}
}
Kostenlos starten →